SBIR/STTR Research Award
Developing antiviral agents that inhibit HCV translation
Award amount
$1,125,290Program and phase
SBIR · Phase IIAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PTC THERAPEUTICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LH7QEHP9V7W1
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): It is estimated that over 170 million people are infected by hepatitis C virus (HCV) worldwide. Currently, there are limited therapeutic agents and no vaccine available for HCV infection. Thus, it is necessary to deve
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Mechanism of nonsense mutation suppression therapy
- Development of an inhibitor of VEGF expression
- A Novel HIV-1 Latency System for Drug Discovery
- Novel Approaches to Identify Anti-Angiogenesis Drugs
- Mechanism of nonsense mutation suppression therapy
Research funding history
13 SBIR/STTR records share this UEI (2000–2006). Reported award amounts total $5,224,297. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services